TKI Resistance for T790M Mutation

TKI Resistance for T790M Mutation

Background and objective Epidermal growth factor receptor (EGFR) the development of orally activesmall molecule inhibitors for non-small cell lung cancer (NSCLC) provides anew treatment plan. EGFR gene mutation in patients with activation EGFR tyrosine kinase inhibitor (EGFR-TKIs) therapy for the tr...

Full description

Bibliographic Details
Main Authors: Hong WANG, Rui GUO, Liyu ZHANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2015-04-01
Series:Chinese Journal of Lung Cancer
Subjects:
Epidermal growth factor receptor
Tyrosine kinase inhibitors
Lung neoplasms
TKI resistance
T790M
Afatinib
Dacomitinib
Erlotinib
Gefitinib
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2015.04.10

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2015.04.10

Similar Items